Lonza Group Ltd Company Profile

04:20 EDT 22nd March 2018 | BioPortfolio

Lonza is continually expanding its scientific and technology base, assigning a high priority to advanced R&D as well as state-of the-art plants and equipment to ensure environmentally safe and quality-minded production. Creative thinking, dedicated staff and sound resources are the strengths that Lonza relies on for further growth. Our people are the key to success – they have extensive expertise in multidisciplinary project management, integrating the wishes and know-how of our customers at every stage.


Muenchensteinerstrasse 38


Phone: 41 61 316 81 11
Fax: 41 61 316 91 11

News Articles [434 Associated News Articles listed on BioPortfolio]

Denali, Lonza collaborate on biologics for neurodegenerative diseases

Denali Therapeutics Inc. is collaborating with Lonza Group Ltd. to advance Denali’s biologic pipeline of neurodegenerative disease compounds through all stages of development and manufacturing.

Lonza to Showcase Its Latest Solutions for Enhanced QC Testing and Transfection at SLAS2018

From 3-7 February 2018, Lonza will be exhibiting at SLAS2018, the annual show hosted by the Society for Laboratory Automation and Screening. At Booth 534 Lonza will showcase how its automated QC testi...

Lonza Announces New Offering of Silensomes™ HLM for Drug Metabolism Studies

Lonza Walkersville announce its new offering of Silensomes™ Human Liver Microsomes (HLM) products – pooled human liver microsomes for in vitro cytochrome P450 (CYP) phenotyping. Lonza Wal...

Lonza posts double-digit organic sales growth

Swiss pharmaceutical and biotech ingredient supplier Lonza today announced its record-breaking 2017 full-year…

Lonza exceeded its full-year 2017 guidance

Lonza today announced its record-breaking 2017 full-year results, which included double-digit organic sales growth, organic CORE EBITDA and CORE EBIT growth well above sales growth and an attractive C...

Lonza, Akouos and MEE Enter Gene Therapy Pact

Lonza and MEE grant Akouos exclusive licenses to proprietary ancestral AAV vectors for all hearing and balance disorders

Lonza Announces New Offering of Silensomes? HLM for Drug Metabolism Studies

Lonza Walkersville’s new Silensomes™ HLM products provide researchers a fully characterized pre-made solution for CYP phenotyping, resulting in more consistent and reliable results

Lonza und Denali Therapeutics schliessen Entwicklungs- und Produktionsabkommen

Eine soeben abgeschlossene Partnerschaft umfasst alle Stufen der Entwicklung und Fertigung, teilte Lonza am Donnerstag mit. Denali erhalte also von der Zelllinienentwicklung bis hin zur Prozessentw...

PubMed Articles [1824 Associated PubMed Articles listed on BioPortfolio]

Transcanalicular laser-assisted dacryocystorhinostomy with diode laser.

This article compares the efficacy of transcanalicular laser assisted dacryocystorhinostomy (TL DCR) with conventional external dacryocystorhinostomy (Ex DCR). All patients were randomly divided into ...

Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative ataxia group, and tremor research group.

Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.

Medulloblastoma, the most common malignant pediatric brain tumor, is a heterogeneous disease, with the existence of at least four molecular types: Wingless (WNT), Sonic Hedgehog (SHH), Group 3 and Gro...

Application of the Pentafluorosulfanyl Group as a Bioisosteric Replacement.

The success of fluorinated molecules in drug design has led medicinal chemists to search for new fluorine-containing substituents. A major recently developed group is the pentafluorosulfanyl group. Th...

Systemic granulomatous disease in dairy cattle during a dicyandiamide feeding trial.

Mature, in-calf, non-lactating, Friesian or Friesian-cross cows were fed dicyandiamide (DCD) at daily doses of 0.15 g/kg (Group 1; n=31), 0.45 g/kg (Group 2; n=21) and 0.75 g/kg (Group 3; n=12), as pa...

Clinical Trials [3529 Associated Clinical Trials listed on BioPortfolio]

The Influence of Hypotensive Drugs on Mineral Status in Experimental and Clinical Studies

The aim of the study was to evaluate the effects of hypotensive treatment combined with a higher zinc supply in the diet and supplements on the mineral status and selected biochemical para...

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

The purpose of this study is to evaluate the safety and tolerability of single oral doses of TAK-828 in healthy non-Japanese and Japanese participants.

Technical Development of Multi-Parametric Renocerebral MRI

The purpose of the study is to investigate the associations of the age-related changes in the brain, kidneys and cognitive performance in healthy adults by utilizing multiple anatomic and ...

Electro-acupuncture and Flumazenil's Effect on Sedation

Object: To explore the mechanism of the electro-acupuncture (EA) induced sedation effect in general anaesthesia through investigating the role of the Benzodiazepines-GABA system. Method: ...

The Effect of Rhubarb on Sepsis and Post-traumatic Gastrointestinal Function Failure

Random grouping by computer, divided into two groups, a group of rhubarb treatment group, another group for the placebo group.

Companies [1602 Associated Companies listed on BioPortfolio]

LONZA Biologics plc

Lonza is continually expanding its scientific and technology base, assigning a high priority to advanced R&D as well as state-of the-art plants and equipment to ensure environmentally safe and quality...

Lonza Group Ltd

Lonza is continually expanding its scientific and technology base, assigning a high priority to advanced R&D as well as state-of the-art plants and equipment to ensure environmentally safe and quality...

Lonza Inc.

Basel, 17.05.2006 - Lonza Group announces the acquisition of assets which comprise Larex, Inc.’s Larch Arabinogalactan business. This strategic acquisition includes among other things, intellectual...

W2 Group, Inc.

W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital ...

PharmEvo (Pvt.) Ltd.

PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...

More Information about "Lonza Group Ltd" on BioPortfolio

We have published hundreds of Lonza Group Ltd news stories on BioPortfolio along with dozens of Lonza Group Ltd Clinical Trials and PubMed Articles about Lonza Group Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lonza Group Ltd Companies in our database. You can also find out about relevant Lonza Group Ltd Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record